IL13RA2 and glioblastoma: Clinical trials are now underway to evaluate the safety and efficacy of this combined approach in GBM patients, including trials using CAR-cells against EGFRvIII with Pembrolizumab (NCT03726515) and CAR-T-cells aimed at IL13Rα2 in conjunction with Nivolumab or Ipilimumab (NCT04003649).